Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX, 77005, USA.
Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA.
Ann Surg Oncol. 2021 Sep;28(9):5297-5310. doi: 10.1245/s10434-021-09622-7. Epub 2021 Feb 3.
Recovery after CRS-HIPEC influenced by several factors, including pain and opioid consumption. We hypothesized that 4Q-TAP blocks provide not inferior quality of recovery compared with TEA after CRS-HIPEC. We conducted a randomized, controlled trial to determine whether 4-quadrant transversus abdominis plane (4Q-TAP) block analgesia was noninferior to thoracic epidural (TEA) among patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC).
Patients 18 years or older who underwent a CRS-HIPEC surgery were randomly assigned to have either TEA or 4Q-TAP blocks. The primary outcome of this study was the change in quality of recovery 2 days after surgery. Secondary outcomes included quality of recovery on Days 1, 3, 5, 7, 10, and 30 postoperatively, opioid consumption, pain intensity, length of stay, and postoperative complications. Analyses were performed on a per-protocol basis.
Sixty-eight patients were included in the analysis. The difference between 4Q-TAP and TEA in the mean QoR-15 change from surgery at postoperative Days 1, 2, and 3 was 0.80 (P = 0.004), -4.5 (P = 0.134), and 3.4 (P = 0.003), respectively. All differences through postoperative day 30 were significantly within the noninferiority boundary of -10 except at postoperative Day 2 (P = 0.134). Length of stay, opioid-related adverse events, and frequency and grade of complications were not significantly different between TEA and 4Q-TAP patients.
Despite the significantly higher use of opioids after CRS-HIPEC in patients with 4Q-TAP blocks, their short-term quality of recovery was not inferior to those treated with TEA. Patients undergoing CRS-HIPEC can be effectively managed with 4Q-TAP blocks.
CRS-HIPEC 后的恢复受多种因素影响,包括疼痛和阿片类药物的使用。我们假设 4Q-TAP 阻滞提供的恢复质量不劣于 CRS-HIPEC 后的 TEA。我们进行了一项随机对照试验,以确定在接受细胞减灭术联合腹腔内热化疗(CRS-HIPEC)的患者中,四象限腹横肌平面(4Q-TAP)阻滞镇痛是否不劣于胸硬膜外(TEA)。
18 岁或以上接受 CRS-HIPEC 手术的患者被随机分配接受 TEA 或 4Q-TAP 阻滞。本研究的主要结局是术后 2 天恢复质量的变化。次要结局包括术后第 1、3、5、7、10 和 30 天的恢复质量、阿片类药物的使用、疼痛强度、住院时间和术后并发症。分析基于方案进行。
68 例患者纳入分析。4Q-TAP 与 TEA 组在术后第 1、2、3 天 QoR-15 评分的平均变化分别为 0.80(P=0.004)、-4.5(P=0.134)和 3.4(P=0.003)。除术后第 2 天(P=0.134)外,所有差异均在-10 的非劣效性边界内。TEA 和 4Q-TAP 患者的住院时间、阿片类药物相关不良事件以及并发症的频率和严重程度均无显著差异。
尽管接受 4Q-TAP 阻滞的患者在 CRS-HIPEC 后阿片类药物的使用明显增加,但他们的短期恢复质量并不劣于接受 TEA 治疗的患者。接受 CRS-HIPEC 的患者可以通过 4Q-TAP 阻滞有效地进行管理。